Scinai Immunotherapeutics (NASDAQ:SCNI) Trading Down 3.1% – What’s Next?

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) shares fell 3.1% during trading on Thursday . The stock traded as low as $0.81 and last traded at $0.8220. 3,069 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 30,237 shares. The stock had previously closed at $0.8479.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scinai Immunotherapeutics in a research note on Thursday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Scinai Immunotherapeutics has an average rating of “Sell”.

Scinai Immunotherapeutics Trading Up 21.9%

The stock has a market cap of $3.19 million, a price-to-earnings ratio of -0.10 and a beta of 1.72. The stock has a 50-day moving average price of $0.90 and a two-hundred day moving average price of $1.34.

Institutional Investors Weigh In On Scinai Immunotherapeutics

A hedge fund recently raised its stake in Scinai Immunotherapeutics stock. Citadel Advisors LLC lifted its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) by 146.8% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned approximately 0.90% of Scinai Immunotherapeutics worth $36,000 at the end of the most recent quarter. Institutional investors and hedge funds own 58.41% of the company’s stock.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.

Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.